Stay updated on BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial
Sign up to get notified when there's something new on the BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial page.

Latest updates to the BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial page
- Check2 days agoChange DetectedExpanded the Study Locations section to include numerous US states and international sites (e.g., Fukuoka, Kanagawa, Nara, Tokyo) and updated the revision to v3.3.3.SummaryDifference1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedPublications sourcing note updated: it now states that publications are automatically filled in from PubMed and may not all be about the study, replacing the previous wording that said publications come from PubMed and are automatically created by ClinicalTrials.gov using the NCT number; Revision changed from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check38 days agoChange DetectedRemoved the government funding and operating status notice from the page; no trial data or essential study details were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page now includes a Results section with results posted (Results First Posted 2022-09-09) and related publications. This provides access to outcomes data.SummaryDifference0.2%

- Check81 days agoChange DetectedMajor update: adds a government funding and operating status notice and marks the page as revision v3.2.0, replacing v3.1.0.SummaryDifference2%

- Check88 days agoChange DetectedAdded version tag v3.1.0 while removing several drug-safety and quality topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), indicating a narrowed content scope despite an updated version.SummaryDifference0.3%

Stay in the know with updates to BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BMS-986036 in NASH Stage 3 Fibrosis Clinical Trial page.